Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pathologic Processes: full-pipeline trial registry
2 of 14 indexed Pathologic Processes trials are currently recruiting.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 2 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Pathologic Processes: 14 US clinical trials tracked, 2 recruiting.
Pathologic Processes is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 3 of these trials.
Enrollment posture brief
Registry condition pathologic-processes
OPEN 2 | RECR 14% | LATE 2 | EARLY 3 | RANK #1230 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Pathologic Processes lists 2 open slots (14% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pathologic Processes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pathologic Processes is recruiting below its size-band peers.
2 of 14 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pathologic Processes research.
University of Colorado, Denver accounts for 3 of 14 trials (21.4%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Pathologic Processes enrolment sits around 177 participants.
Median target enrolment is 177 among the 14 trials that report a genuine target (sentinel values excluded). 5 of those (35.7%) plan for fewer than 100 participants.
-
Pathologic Processes research is mostly interventional.
11 interventional and 3 observational studies make up this index (78.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
C5 Biomedical
NCT06674980
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Brigham and Women's Hospital
NCT06252129
Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients
University of Colorado, Denver
NCT04534959
Strategy to Avoid Excessive Oxygen in Major Burn Patients
University of Colorado, Denver
NCT04534972
Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention
University of Colorado, Denver
NCT06374225
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
University of Rochester
NCT04922281
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Cumberland Pharmaceuticals
NCT02682511
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Cancer Institute (NCI)
NCT05797246
Pivotal Study for Validation of Philips Dx (PDx)
Philips Digital & Computational Pathology
NCT02529137
pRESET for Occlusive Stroke Treatment
phenox
NCT03994822
Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00776412
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
Indiana University
NCT02685098
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Dragonfly Research
NCT04837651
Adapting Connect-Home Transitional Care for the Unique Needs of Persons With Alzheimer's Disease and Other Dementias and Their Caregivers
University of North Carolina, Chapel Hill
NCT05887388
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pathologic Processes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pathologic Processes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pathologic Processes page
14 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Pathologic Processes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Colorado, Denver sponsors the most Pathologic Processes trials on record, review their full trial history before evaluating a specific study. See University of Colorado, Denver's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pathologic Processes condition card totals 14 registered trials; most-linked intervention Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.